NasdaqGS - Nasdaq Real Time Price • USD
Dynavax Technologies Corporation (DVAX)
As of 12:36 PM EDT. Market Open.
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 4 | 4 | 5 | 5 |
Avg. Estimate | -0.02 | 0.09 | 0.25 | 0.5 |
Low Estimate | -0.06 | 0.03 | 0.15 | 0.29 |
High Estimate | 0.01 | 0.11 | 0.35 | 0.74 |
Year Ago EPS | -0.19 | 0.03 | -0.05 | 0.25 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 4 | 4 | 5 | 5 |
Avg. Estimate | 54.97M | 78.37M | 287.96M | 347.37M |
Low Estimate | 50.71M | 76.33M | 273.1M | 314.02M |
High Estimate | 58.44M | 80M | 301.07M | 376.34M |
Year Ago Sales | 38.59M | 48.38M | 232.28M | 287.96M |
Sales Growth (year/est) | 42.40% | 62.00% | 24.00% | 20.60% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.13 | -0.09 | -0.01 | -0.01 |
EPS Actual | -0.19 | 0.03 | 0.1 | 0 |
Difference | -0.06 | 0.12 | 0.11 | 0.01 |
Surprise % | -46.20% | 133.30% | 1,100.00% | 100.00% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.02 | 0.09 | 0.25 | 0.5 |
7 Days Ago | -0.02 | 0.09 | 0.25 | 0.5 |
30 Days Ago | -0.02 | 0.09 | 0.26 | 0.51 |
60 Days Ago | 0 | 0.09 | 0.24 | 0.5 |
90 Days Ago | 0.02 | 0.06 | 0.22 | 0.41 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | DVAX | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 89.50% | -- | -- | 1.50% |
Next Qtr. | 200.00% | -- | -- | 12.10% |
Current Year | 600.00% | -- | -- | 4.40% |
Next Year | 100.00% | -- | -- | 13.20% |
Next 5 Years (per annum) | -- | -- | -- | 10.97% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Initiated | Goldman Sachs: Neutral | 2/1/2024 |
Maintains | JMP Securities: Market Outperform to Market Outperform | 11/3/2023 |
Maintains | HC Wainwright & Co.: Buy to Buy | 11/3/2023 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 8/4/2023 |
Maintains | JMP Securities: Outperform to Outperform | 8/4/2023 |
Maintains | JMP Securities: Outperform | 5/3/2023 |
Related Tickers
EOLS Evolus, Inc.
11.34
-1.05%
DCPH Deciphera Pharmaceuticals, Inc.
14.53
+2.47%
ESPR Esperion Therapeutics, Inc.
1.9300
-3.02%
AVDL Avadel Pharmaceuticals plc
17.98
+0.90%
ELAN Elanco Animal Health Incorporated
13.27
+1.76%
AQST Aquestive Therapeutics, Inc.
4.0543
+3.16%
NBIX Neurocrine Biosciences, Inc.
136.37
-1.01%
VTRS Viatris Inc.
11.57
+0.91%
TEVA Teva Pharmaceutical Industries Limited
13.79
+4.04%
ALKS Alkermes plc
24.56
+0.47%